HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
|Articles|June 10, 2022
Daily OTC Pearl: IBS Complete Support
Author(s)Saro Arakelians, PharmD
IBS Complete Support helps relieve abdominal pain, bloating, and constipation associated with irritable bowel syndrome.
Advertisement
OTC/Lifestyle Pearl of the Day: IBS Complete Support
Indication: IBS Complete Support helps relieve abdominal pain, bloating, and constipation associated with irritable bowel syndrome (IBS).
Insight:
- Flavored packets are for once-daily use.
- Helps provide relief for constipation or diarrhea related to IBS.
- Odorless powder.
Source:
Advertisement
Related to this article
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
2
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
New Data Reshapes Nonstatin Lipid Therapy Choices
5